VANCOUVER, British Colombia - November 14, 2012 - Garmatex Technologies, Inc. ("Garmatex" or the "Company") is an innovative leader in the research and development of scientifically engineered, performance-inspired fabric technologies. ...
Tags: garment and performance wear technologies, designer wear, workwear
Zogenix has commenced first IND clinical trial for Relday in patients with chronic, stable schizophrenia or schizoaffective disorder. Relday is based on a combination of its DosePro needle-free, subcutaneous drug delivery system with a ...
Tags: Clinical Trial, DosePro needle-free drug, pharmacokinetic
Janssen Biotech has signed a license agreement with Astellas Pharma for the worldwide development and commercialization of ASP015K, except in Japan. Astellas will continue development and commercialization of ASP015K in Japan. ASP015K, ...
Tags: Janssen Biotech, Astellas Pharma, license agreement, ASP015K
Skuldtech and AB Science have discovered a new set of blood markers predictive of a higher survival rate in pancreatic cancer patients. The companies are also planning to use the new markers for future companion test commercialization ...
Tags: skuldtech, AB science, blood markers, pancreatic cancer patients
CRAiLAR Technologies Inc.confirmed that it will commission the Company's first full-scale manufacturing facility for CRAiLAR Flax Fiber on December 17,2012.Announced on its investor call in October,the timeline remains in place to begin ...
Tags: CRAiLAR, flax fiber, textile, material
Mobius Therapeutics, an ophthalmic company, has begun commercial shipments of Mitosol (mitomycin for solution) kit for ophthalmic use. Mitosol will provide a new system for delivering a precise dose of its active ingredient, mitomycin-c, ...
Galapagos, a mid-size biotechnology company, has delivered the first pre-clinical candidate compound in its osteoarthritis alliance with Servier. Servier and Galapagos entered into an alliance in July 2010 to develop new oral medicines ...
Tags: Galapagos Identifies Drug, Galapagos, Servier, osteoarthritis
The assets were purchased from Twin Creeks’ lenders in a private sale for approximately $10 million and royalties that will be based on future sales. GT expects that Twin Creeks’ unique Hyperion™ ion implanter ...
Tags: GT, Twin Creeks, Vikram Singh
Forest Laboratories and Adamas Pharmaceuticals have collaborated for the development of a fixed dosed combination (FDC) of Namenda XR and donepezil HCl for Alzheimer's dementia in the US. The company expects to launch the FDC that will be ...
Daiichi Sankyo has signed an exclusive agreement with Coherus BioSciences to develop and commercialize biosimilar candidates in certain Asian countries including Japan. The collaboration will focus on the development, manufacturing and ...
Tags: Daiichi Sankyo, Coherus BioSciences, biosimilar candidates
PTC announced that Cabela's, the world's largest direct marketer of hunting, fishing, camping and related outdoor merchandise, has chosen PTC Windchill FlexPLM software, PTC's Product Lifecycle Management (PLM) solution for retail, to ...
Tags: United States of America, Cabela, PTC PLM Tool, Creativity&Innovation
ITV Denim, known for its commitment to innovation, has partnered with INVISTA and ECOYAA to produce a new range of denim fabrics that uses wine and its derivatives to achieve color. The new process replaces traditional synthetic indigo ...
Tags: United Kingdom, New Technology, Wine Derivates, Denim Colours
Baxter International has collaborated with Chatham Therapeutics for the development and commercialization of factor IX hemophilia B gene therapy treatment. According to the agreement, the companies will investigate the next generation of ...
Tags: IX hemophilia B gene therapy, Biological Nano Particles, clinical trials
Pfizer has granted exclusive development and marketing rights to ChemRar group company SatRx for their DPP(1)-IVi compound, PF-00734200 for type 2 diabetes (T2D). T2D is one of the most burdensome chronic non-communicable diseases, which ...
Tags: Satrx Exclusive License, epidemic proportions, R&D portfolio
Unilife has developed two new technologies for delivering injectable therapies to targeted regions of the eye. The new technologies include Unilife Depot-Ject platform which allows clinicians to implant a solid or oil based drug into the ...